Oncology

#Cell and gene therapy #Clinical trials #Oncology

Sitting down with Calidi Biotherapeutics

Listen to this article on the DDW Podcast: Dr Boris Minev, President of Medical and Scientific Affairs at Calidi Biotherapeutics speaks to DDW’s Reece Armstrong about the company’s approach to treating cancer. RA: Could you give us an idea of your current pipeline? BM: Calidi Biotherapeutics’ current pipeline consists of oncolytic… Read More

#Exclusive Content

#DNA #Institute of Cancer Research #Oncology

Junk DNA could lead to cancer, study says  

Non-coding or ‘junk’ DNA could contribute to the development of certain cancers due to how it disrupts the replication of the genome, scientists have discovered.   A team from The Institute of Cancer Research (ICR), London reconstituted the entire process of DNA replication in a test tube in… Read More

#News #Trending News

Back pain
#AstraZeneca #DNA #Oncology

Could this drug help repair nerve damage?  

Research from the University of Birmingham in the UK has indicated that a cancer therapy could help damaged nerves repair themselves following spinal injury.   The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged… Read More

#News #Trending News

Bladder
#Cancer immunotherapy #Oncology #Regulatory

The avelumab story and what it means for urothelial carcinoma

Listen to this article on the DDW Podcast: Following the announcement that Merck & Pfizer’s immunotherapy drug avelumab has been approved by National Institute for Health and Care Excellence (NICE) in the UK, Lu Rahman speaks to Dr Stuart Hill, Medical Director for Merck, about the development of the drug and… Read More

#Exclusive Content

#Acquisition #GSK #Oncology

GSK completes acquisition of Sierra Oncology  

GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.  The deal was announced back in April this year and sees GSK acquiring Sierra Oncology for a total of $1.9 billion. The acquisition will give GSK access to Sierra’s late-stage candidate momelotinib, which… Read More

#Business & Investment #News

#Biomarkers #mRNA #Oncology

First patient enrolled in mRNA biomarker study for cancer  

Molecular genetics company Mainz Biomed has enrolled its first patient in an international clinical study assessing the potential combination of gene expression (mRNA) biomarkers with a diagnostic test for colorectal cancer.  The ColoFuture clinical study will see Mainz Biomed integrate a portfolio of novel gene expression (mRNA)… Read More

#News

#CAR-T #European Commission #Oncology

European Commission approves Yescarta  

The European Commission (EC) has approved biotechnology company Kite’s CAR T-cell therapy Yescarta for patients with follicular lymphoma (FL).  Specifically the approval is for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.  The approval was based… Read More

#News

#Biologics / Biotechnology #Cancer #Oncology #Podcast

Latest DDW podcast: The pursuit of better cancer treatments

This is the latest episode of the free DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and “Biotech’s pursuit of… Read More

#News

#Biotechnology #Cell therapy #Narrated podcasts #Oncology

The pursuit of better cancer treatments

This is the latest episode of the free narrated DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and… Read More

#Podcasts

Mammography
#Breast cancer #Eli Lilly #Oncology

UK’s NICE recommends Eli Lilly’s breast cancer drug  

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with… Read More

#News

Stamp of approval
#Drug approvals #MHRA #Novartis #Oncology

MHRA approves Novartis treatment for CML  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Novartis UK’s treatment for a specific type of cancer.  The authorisation was granted for Scemblix (asciminib), Novartis UK’s therapy for adults with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who have previously been treated… Read More

#News #Regulatory

#Antibody drug conjugate (ADC) #Diagnostics #Oncology

This week in drug discovery (13-17 June)

News round-up by DDW’s Reece Armstrong for 13-17 June. Partnerships, awards, and new companies are some of the topics of this week’s news round-up. Bachem & Eli Lilly partner on oligonucleotide project Swiss pharmaceutical company Bachem has partnered with Eli Lilly on a seven-year agreement to advance the development of… Read More

#News

#Antibody drug conjugate (ADC) #Investment #Oncology

Spirea raises £2.4m to develop ADC cancer therapies  

A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.  Spirea is developing ACD therapeutics for solids tumours with a high unmet need. The company has developed technology that enables more cytotoxic drug to… Read More

#Business & Investment #News

#Oncology #Small molecules

Lead Pharma and Oxeltis receive €800K for cancer project  

Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.  Lead Pharma and Oxeltis were awarded the funding from EUREKA Eurostars for their three-year EPIGENEXT joint project.   Through the project,… Read More

#News

#Clinical trials #Leukaemia #Oncology

Nurix expands protein degrader into CLL   

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK)… Read More

#News